Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
October 03 2022 - 6:00AM
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology
company developing induced pluripotent stem cell (iPSC)-derived
cell therapies in immuno-oncology, today announced the appointment
of Daphne Quimi and Timothy Walbert to the Company’s Board of
Directors. Ms. Quimi is currently Chief Financial Officer of Amicus
Therapeutics and brings experience in public accounting and
financial reporting to Century. Mr. Walbert is currently Chairman,
President, and Chief Executive Officer of Horizon Therapeutics, and
brings expertise in product portfolio building and
commercialization. In conjunction with these new appointments,
Century also announced that Eli Casdin, Chief Investment Officer of
Casdin Capital, has resigned from the Board of Directors, effective
as of October 1, 2022.
“I am thrilled to welcome both Daphne and Tim to
our Board. They will each play critical roles as we accelerate our
next-generation cell therapy platform,” said Lalo Flores, Ph.D.,
Chief Executive Officer, Century Therapeutics. “Daphne’s strong
financial background and experience at both biotechnology and large
pharmaceutical companies will be a tremendous asset as we enter the
next transformative years for Century. Tim’s background, which
includes numerous product launches, will be instrumental to our
continued evolution, particularly as we progress our pipeline
candidates with the ultimate goal of delivering innovative cancer
therapies. Additionally, on behalf of the management, Board and all
of our employees, we would like to thank Eli for his contributions
to Century’s rapid growth and his leadership in our early formative
years, where he was a key strategic thought partner.”
Before serving as Amicus’s Chief Financial officer,
Ms. Quimi was Amicus’s Senior Vice President, Finance and Corporate
Controller. Ms. Quimi is currently a member of the Board of
Directors at Amylyx Pharmaceuticals. Prior to Amicus, Ms. Quimi
served as Director of Consolidations and External Reporting at
Bristol-Myers Squibb. She also held roles of increasing
responsibility in the finance department at Johnson & Johnson.
Earlier in her career she worked for KPMG. Ms. Quimi received a
B.S. in Accountancy from Monmouth University and an M.B.A from the
Stern School of Business of New York University.
In addition to his current role of President and
Chief Executive Officer of Horizon Therapeutics, Mr. Walbert has
served as Chairman of Horizon’s Board of Directors since 2010.
Before joining Horizon, Mr. Walbert served as President, Chief
Executive Officer and Director of IDM Pharma Inc., and also held
prior senior roles at NeoPharm Inc., Abbott (AbbVie), G.D. Searle
& Company, Merck & Co. Inc. and Wyeth. Mr. Walbert received
a B.A. in Business from Muhlenberg College.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing
the power of adult stem cells to develop curative cell therapy
products for cancer that we believe will allow us to overcome the
limitations of first-generation cell therapies. Our genetically
engineered, iPSC-derived iNK and iT cell product candidates are
designed to specifically target hematologic and solid tumor
cancers. We are leveraging our expertise in cellular reprogramming,
genetic engineering, and manufacturing to develop therapies with
the potential to overcome many of the challenges inherent to cell
therapy and provide a significant advantage over existing cell
therapy technologies. We believe our commitment to developing
off-the-shelf cell therapies will expand patient access and provide
an unparalleled opportunity to advance the course of cancer care.
For more information on Century Therapeutics please visit
www.centurytx.com.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking
statements within the meaning of, and made pursuant to the safe
harbor provisions of, The Private Securities Litigation Reform Act
of 1995. In some cases, you can identify forward-looking statements
by terms such as “may,” “might,” “will,” “should,” “expect,”
“plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“forecast,” “potential” or “continue” or the negative of these
terms or other similar expressions. These statements are not
guarantees of future performance These risks and uncertainties are
described more fully in the “Risk Factors” section of our most
recent filings with the Securities and Exchange Commission and
available at www.sec.gov. You should not rely on these
forward-looking statements as predictions of future events. The
events and circumstances reflected in our forward-looking
statements may not be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. Except as required by applicable law, we do not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
For More Information:
Company: Elizabeth Krutoholow –
investor.relations@centurytx.com
Investors: Melissa Forst/Maghan Meyers –
century@argotpartners.com
Media: Joshua R. Mansbach –
century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Apr 2024 to May 2024
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From May 2023 to May 2024